ChemicalBook >> CAS DataBase List >>AM-9022

AM-9022

AM-9022 structure

CAS No.: 2446872-46-2

Chemical Name:: AM-9022

Synonyms: AM-9022;Benzamide, 2-(6-azaspiro[2.5]oct-6-yl)-N-[2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl]-4-[[[(1R)-2-hydroxy-1-methylethyl]sulfonyl]amino]-

CBNumber:: CB413900500

Molecular Formula:: C27H36F2N6O4S

Molecular Weight:: 578.68

MDL Number:

MOL File:: 2446872-46-2.mol

MSDS File:: SDS

Last updated:2025-05-19 13:47:39

Request For Quotation

AM-9022 Properties

Density	1.425±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
pka	7.199±0.10(predicted)
form	Solid
color	White to off-white

AM-9022 price

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
ChemScene	CS-0927871	AM-9022 99.53%	2446872-46-2	5mg	$213	2026-06-04	Buy
ChemScene	CS-0927871	AM-9022 99.53%	2446872-46-2	10mg	$298	2026-06-04	Buy
ChemScene	CS-0927871	AM-9022 99.53%	2446872-46-2	25mg	$538	2026-06-04	Buy
ChemScene	CS-0927871	AM-9022 99.53%	2446872-46-2	50mg	$747	2026-06-04	Buy
ChemScene	CS-0927871	AM-9022 99.53%	2446872-46-2	100mg	$1051	2026-06-04	Buy

Product number	Packaging	Price	Buy
CS-0927871	5mg	$213	Buy
CS-0927871	10mg	$298	Buy
CS-0927871	25mg	$538	Buy
CS-0927871	50mg	$747	Buy
CS-0927871	100mg	$1051	Buy

AM-9022 Chemical Properties, Uses, Production

Uses

AM-9022 is an orally active, potent, selective KIF18A inhibitor that can be used for research on cancer[1].

in vivo

AM-9022 (30-100 mg/kg; p.o.; daily for 18 or 21 days) has significant anti-cancer effects in breast and ovarian tumor models at well-tolerated doses^[1].

Animal Model:	Female athymic nude mice were injected with OVCAR-3 cells (5 x 10⁶) subcutaneously in the right flank. Femal CB.17 SCID mice were injected with JIMT-1 cells (1.0×10⁷) subcutaneously in the right flank) (6-8 weeks)^[1]
Dosage:	30 mg/kg (OVCAR-3 CDX tumors mice); 30, 100 mg/kg (JIMT-1 tumors mice)
Administration:	Oral gavage (p.o.); daily for 18 days or 21 days
Result:	Increased pH3 mitotic marker levels in OVCAR-3 tumors by 3.4-fold, with higher compound exposure in tumors relative to plasma in OVCAR-3 CDX tumors mice. Inhibited tumor growth, with evidence of tumor regression (TR) (95% TR, six of ten tumor-free mice) and no body weight loss in OVCAR-3 CDX tumors mice. Inhibited tumor growth with evidence of TR (16% and 94% TR, respectively) at well-tolerated doses in JIMT-1 tumors mice. The plasma AUC value at 30mg/kg was 3.7-fold higher in the JIMT-1 model relative to the OVCAR-3 model.

References

[1] Payton M, et al. Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers. Nat Cancer. 2023 Dec 27. DOI:10.1038/s43018-023-00699-5

AM-9022 Preparation Products And Raw materials

Raw materials

Preparation Products

AM-9022 Suppliers

Global Suppliers ( 3)

Supplier	Tel	Email	Country	ProdList	Advantage
Nantong QuanYi Biotechnology Co., Ltd	0513-66337626 18051384581	sales@chemhifuture.com	China	5985	58
TargetMol Chemicals Inc.	15002134094	marketing@targetmol.cn	China	29874	58

Supplier	Advantage
Nantong QuanYi Biotechnology Co., Ltd	58
TargetMol Chemicals Inc.	58

2446872-46-2 (AM-9022) Related Search:

Benzamide, 2-(6-azaspiro[2.5]oct-6-yl)-N-[2-(4,4-difluoro-1-piperidinyl)-4-pyridinyl]-4-[[(2-hydroxyethyl)sulfonyl]amino]- AM-9022 Benzamide, 2-(6-azaspiro[2.5]oct-6-yl)-N-[2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl]-4-[[[(1S)-2-hydroxy-1-methylethyl]sulfonyl]amino]- Sovilnesib Ispinesib

MonoMethyl auristatin E

1of2

AM-9022 Benzamide, 2-(6-azaspiro[2.5]oct-6-yl)-N-[2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl]-4-[[[(1R)-2-hydroxy-1-methylethyl]sulfonyl]amino]- 2446872-46-2